CAJ | 학술논문

目的：通过检测miR-196b在初诊急性髓系白血病(AML)患儿中的表达，评估miR-196b在儿童AML中的临床意义。方法从标本库中抽取52例初诊AML患儿骨髓，利用qRT-PCR方法检测miR-196b表达水平(结果以2-??Ct表示)，并与同期30例非白血病患儿标本对照。结果单核系组(M4、M5)的miR-196b表达水平高于非单核系组(M1、M2、M3、M6、M7)和对照组，而非单核系组低于对照组，差异均有统计学意义(P<0.01)。miR-196b表达水平在t(15；17)组最低，11q23(MLL)组最高，差异有统计学意义(P<0.01)。使用NCCN2013预后分组标准，预后良好组miR-196b表达低于预后不良组，差异有统计学意义(P<0.01)。首疗程缓解组miR-196b表达明显低于首疗程未缓解组，差异有统计学意义(P<0.05)。WBC≥100×109/L组miR-196b表达水平高于WBC<100×109/L组，差异有统计学意义(P<0.01)。miR-196b表达水平与初诊时血小板计数呈显著正相关(r=0.302，P=0.030)。结论 miR-196b表达水平在初诊AML预后不良组明显增高，高水平的miR-196b与低缓解率和较差的预后相关。miR-196b有望成为AML患儿治疗新靶点。
목적：통과검측miR-196b재초진급성수계백혈병(AML)환인중적표체，평고miR-196b재인동AML중적림상의의。방법종표본고중추취52례초진AML환인골수，이용qRT-PCR방법검측miR-196b표체수평(결과이2-??Ct표시)，병여동기30례비백혈병환인표본대조。결과단핵계조(M4、M5)적miR-196b표체수평고우비단핵계조(M1、M2、M3、M6、M7)화대조조，이비단핵계조저우대조조，차이균유통계학의의(P<0.01)。miR-196b표체수평재t(15；17)조최저，11q23(MLL)조최고，차이유통계학의의(P<0.01)。사용NCCN2013예후분조표준，예후량호조miR-196b표체저우예후불량조，차이유통계학의의(P<0.01)。수료정완해조miR-196b표체명현저우수료정미완해조，차이유통계학의의(P<0.05)。WBC≥100×109/L조miR-196b표체수평고우WBC<100×109/L조，차이유통계학의의(P<0.01)。miR-196b표체수평여초진시혈소판계수정현저정상관(r=0.302，P=0.030)。결론 miR-196b표체수평재초진AML예후불량조명현증고，고수평적miR-196b여저완해솔화교차적예후상관。miR-196b유망성위AML환인치료신파점。
Objective To evaluate the expression of miR-196b in newly diagnosed pediatric acute myeloid leukemia (AML) and its clinical signiifcance. Methods Fifty-two AML children were enrolled in this study and 30 non-leukemia com-pared children were selected as controls. The expressions of miR-196b were detected in bone marrow samples by real-time quan-titative PCR (q-RT-PCR) and the results were expressed in 2-??Ct. Results miR-196b expressions were signiifcantly higher in M4-5 and lower in non-M4-5 of AML children than those in control (P<0.01), with a lowest level in t (15;17) and a highest level in MLL subtypes (P<0.01). The miR-196b expressions were signiifcantly different among different prognosis groups (P<0.01) and the level in the favorable prognostic group was lower than in poor prognosis group. It was also found that miR-196b expres-sion was lower in remission group than that in no-remission group after the ifrst induction remission therapy (P<0.05). Mean-while, the expression of miR-196b in the children with WBC≥100×109/L were statistically higher than that in the children with WBC<100×109/L (P<0.01), and miR-196b level was positively correlated with the platelet counts (r=0.302, P=0.030). Conclu-sions miR-196b expression is increased in poor prognosis group of AML children, and high expression of miR-196b is related with low response rate and poor prognosis. miR-1966 is expected to become a new target for the treatment of AML.